Page last updated: 2024-12-06

cupric hydroxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

copper hydroxide: used as an antifungal agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164826
CHEBI ID81907
MeSH IDM0041860

Synonyms (22)

Synonym
cupric hydroxide
copper hydroxide
C18712
pei 24
einecs 215-705-0
1344-69-0
copper(i) hydroxide
copper monohydroxide
cuprous hydroxide
12125-21-2
cupric hydroxide [mi]
hydrated cupric oxide
chebi:81907 ,
JJLJMEJHUUYSSY-UHFFFAOYSA-L
copper (ii) hydroxide
J-520119
AKOS030228342
J-013306
cuprichydroxide
Q186357
copper;dihydroxide
copper(i)hydroxide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Thus, our results suggest CuOH(+) was highly toxic to barley root elongation."( Identification of hydroxyl copper toxicity to barley (Hordeum vulgare) root elongation in solution culture.
Hua, L; Ma, Y; McLaughlin, MJ; Wang, X, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The amount of immobilized heparin on nanofiberous membrane was determined by a colorimetric assay of toluidine blue dye and the results showed that the amount of immobilized heparin was strongly dependent on the heparin dosage in reaction solution."( Hemocompatible and antibacterial porous membranes with heparinized copper hydroxide nanofibers as separation layer.
Jiang, JH; Xu, YY; Yi, Z; Zhu, BK; Zhu, LJ; Zhu, LP, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (4.65)18.7374
1990's3 (3.49)18.2507
2000's19 (22.09)29.6817
2010's40 (46.51)24.3611
2020's20 (23.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other87 (98.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]